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Abstract
Type I diabetes is caused by loss of insulin-secreting beta cells. To identify novel, pharma-
cologically-targetable histone-modifying proteins that enhance beta cell production from
pancreatic progenitors, we performed a screen for histone modifications induced by signal
transduction pathways at key pancreatic genes. The screen led us to investigate the tempo-
ral dynamics of ser-28 phosphorylated histone H3 (H3S28ph) and its upstream kinases,
MSK1 and MSK2 (MSK1/2). H3S28ph and MSK1/2 were enriched at the key endocrine and
acinar promoters in E12.5 multipotent pancreatic progenitors. Pharmacological inhibition of
MSK1/2 in embryonic pancreatic explants promoted the specification of endocrine fates,
including the beta-cell lineage, while depleting acinar fates. Germline knockout of both Msk
isoforms caused enhancement of alpha cells and a reduction in acinar differentiation, while
monoallelic loss of Msk1 promoted beta cell mass. Our screen of chromatin state dynamics
can be applied to other developmental contexts to reveal new pathways and approaches to
modulate cell fates.
Introduction
Cell fate specification during development involves activation and repression of specific gene-
regulatory networks, which are driven by changes in extracellular environment. Dynamics in
such networks are mediated by lineage-specific transcription factors that recruit, among other
proteins, histone-modifying enzymes to relevant loci [1, 2]. In many instances, the histone-
modifying enzymes are themselves regulated by changes in the extracellular environment, thus
mediating responses to inductive cues [3–6]. The loss of function or pharmacological inhibi-
tion of histone modifying enzymes in the progenitors of various lineages has been shown to
modulate their eventual fate choice [7, 8]. We examined histone modifications induced by sig-
naling pathways in the pancreatic beta cell progenitors, focusing on genes that are key drivers
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of different pancreatic lineages, with the aim of identifying pharmacologically-targetable his-
tone modifiers that could promote pancreatic beta cell development.
MSK1/2 (Mitogen and Stress-induced Kinase) are partially redundant serine/threonine
kinases that are phosphorylated downstream of MAPK (Erk and/or p38-mediated) and cAMP
signal transduction pathways. Phosphorylated-MSK1/2 can, in turn, directly phosphorylate
histone H3 at Ser10 and Ser28 residues, leading to transcriptional activation [9–18]. Yet recent
reports also indicate the association of H3S10ph and H3S28ph with transcriptionally silent
genes, suggesting context-dependent association of these modifications with the transcrip-
tional status of a gene [19, 20]. The dynamics of MSK1/2-mediated H3S28 and H3S10 phos-
phorylation have been well characterized in signal-mediated transcriptional regulation in
mammalian fibroblasts and Drosophila salivary glands (see references above), but their role
has not been examined during pancreatic development in any metazoan.
Mouse pancreatic development begins with the specification of multipotent progenitors
that co-express transcription factors Pdx1, Ptf1a, Cpa1, Oc1, and Sox9 from 8.5 to 12.5 embry-
onic days of gestation (E8.5 to E12.5) [21–27]. During subsequent morphogenesis, proacinar
exocrine precursors are restricted to the tips of branching pancreatic epithelia co-expressing
Ptf1a, Cpa1, Nr5a2, Gata4, and Mist1. These genes orchestrate steps related to acinar differen-
tiation, morphogenesis, and growth [27–32]. Sox9 and Nkx6.1 are expressed in the branching
trunk domain, containing progenitors for duct and endocrine cell lineages [27, 33–35]. Oc1
and Pdx1 are co-expressed in the acinar precursors until E16.5. Subsequently, their expression
diminishes in the acinar cells and increases in the duct and Insulin1/2 positive beta cell line-
ages, respectively, in the neonates [36–42].
All pancreatic endocrine cell types, including the beta cell lineage, are specified by the tran-
scription factor Neurogenin3 (Neurog3), which in turn activates other endocrine progenitor
genes, such as Pax6, NeuroD1, Insm1, and Rfx6 [43–48]. These endocrine progenitors differen-
tiate into glucagon (Gcg)-producing alpha cells throughout pancreatic development, while the
majority of mature insulin1 (Ins1/2) producing beta cells arise only after E13.5 [49–51]. The
mature beta cells subsequently express high levels of MafA, Glut2, and Pcsk1 [52,53].
In this study, we sought to identify novel regulators of beta cell specification, focusing on
histone modifying enzymes that were previously identified as effectors of signal transduction
pathways. To this end, we performed a screen for signaling-induced histone modifications at
genes involved in the differentiation of pancreatic lineages. We found enrichment of
H3S28ph, at the Pdx1 promoter and at the Pdx1 area II enhancer (Pdx1enh) in E12.5 multipo-
tent pancreatic progenitors. The Pdx1enh is necessary for differentiation of the beta cell lineage
[54–60]. The Ptf1a gene, critical for acinar cell specification [27–29], and acinar-cell specific
Amylase2a (Amyl) promoter were enriched for H3S28ph in E12.5 multipotent pancreatic pro-
genitors. In pancreatic explants harvested from E12.5 and E15.5 stages of pancreatic develop-
ment, pharmacological inhibition of Mitogen and Stress Activated Kinase (MSK1/2), an
upstream chromatin modifier of H3S28ph and H3S10ph, using SB-747541A, caused a strong
induction of the endocrine fates, including the beta-cell lineage, while suppressing acinar fates.
Germline knockouts of both Msk1 and Msk2 led to a decrease in acinar mass with an increase
in alpha cell mass, consistent with alpha cells being the preferentially specified endocrine fate
early in pancreatic development [51]. In accord with the robust induction of beta cell mass
upon SB-747541A treatment at E15.5, monoallelic knockout of Msk1 showed an enhancement
of beta cell mass. Altogether, we find that the chromatin modifiers MSK1 and MSK2 normally
promote acinar and suppress endocrine differentiation during pancreatic development, and
that pharmacologic inhibition of MSK proteins can markedly enhance beta cell production at
the later stage of endocrine differentiation. Our analysis of chromatin state dynamics can be
applied to other developmental contexts to discover new ways to modulate cell fate decisions.
Msk Represses Pancreatic Beta Cell Fate
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Results
A screen for histone modifications induced by signaling pathways
We predicted that performing a screen for signaling-induced histone modifications in pancre-
atic progenitors would reveal chromatin modifiers and signaling pathways that modulate beta
cell induction, and that pharmacologic or genetic targeting of relevant modifiers could enhance
beta cell production. To establish the screen, we considered Onecut1 (Oc1) as a potential
marker to purify pancreatic epithelial cells, at E15.5, by Fluorescence Activated Cell Sorting
(FACS). Using FACS, we separated the Oc1 positive cells, excluding Oc1 negative mesenchymal
and maturing beta-cells. We verified by immunohistochemistry that only a minor 4.6% of total
Ins1/2 positive cells were Oc1 positive at E15.5 stage of pancreatic development, consistent with
other reports (S1A–S1C Fig, n = 3 pancreas, # of sections/pancreas = 5, [39–42]). Other lineage
tracing studies have indicated that the Oc1+ trunk cells harbors progenitors of the mature beta-
cell lineage [33–35]. Therefore, a screen for signaling induced histone modifications at key pan-
creatic lineage-specific genes in the Oc1+ epithelial progenitors could reveal signaling pathways
that direct the induction of pancreatic progenitors towards the beta cell fates [1, 3–7].
For FACS sorting, a fluorophore-conjugated secondary antibody, lacking the Fc region,
was used to stain and sort cells [61]. This step ensured that the chromatin bound by anti-Oc1
antibodies was not immunoprecipitated by Protein G agarose beads during a subsequent chro-
matin immunoprecipitation (ChIP) reaction. Also, the cells were fixed immediately after disso-
ciation, prior to FACS, precluding any effects that may arise in the time after dissociation and
sorting. The sort was done in Pdx1:Egfp [62] pancreata, enabling subsequent work, but we did
not sort for Egfp in this screen (x-axis, Fig 1A). The Oc1+ population showed significantly
higher expression of trunk and future duct genes Oc1 and Sox9 by RT-qPCR, indicating that
we have enriched for Oc1+ cells by FACS (Fig 1A and 1B).
Next, we examined histone modifications induced by known signal transduction pathways
(Table 1) by ChIP in the FACS-enriched Oc1+ population (Fig 1C–1J, n25 pooled pancreata
for ChIP, n = 3 technical replicates). All P-values were calculated by a paired Student’s t test.
H3S28ph was enriched at the promoters active in endocrine lineages, including Insulin1 (Ins1,
P-value = 0.05), Insulin2 (Ins2, P-value = 0.05), Neurog3 (P-value = 0.07), and the Pdx1enh
(P-value = 0.03), and also at the acinar specific Amyl promoter (P-value = 0.04, Fig 1C, Table 1).
H3S10ph showed enrichment similar to H3S28ph at promoters for Ins1 (P-value = 0.005), Ins2
(P-value = 0.02), Neurog3 (P-value = 0.002), Pdx1enh (P-value = 0.04), and Amyl, (P-value = 0.03,
Fig 1D, Table 1) genes. The gene promoters active in trunk and future duct cells, such as Sox9 and
Oc1, were neither enriched for H3S28ph nor H3S10ph (ChIP data summarized in Table 1). Con-
versely, H3K79me2 [63, 64] was significantly enriched at the promoters active in trunk and future
duct epithelial cells, such as Sox9 (P-value = 0.01), and Oc1 (P-value = 0.01). The beta cell specific
Pdx1enh (P-value = 0.03), and acinar specific Amyl promoters were enriched for H3K79me2
as well (P-value = 0.05), Fig 1E, Table 1). H4R3me2 [65–67], H3K18ac [68], H3K9acS10ph,
H3K9ac, and H3K27ac were significantly enriched at all the promoters examined and thus lacked
specificity (Fig 1F–1J, Table 1). We focused on further investigating the dynamics of HS28ph and
H3S10ph in purified E12.5 multipotent progenitors due to their enrichment at the endocrine and
acinar specific promoters, and the relative lack at the ductal promoters, with the aim to identify
chromatin modifiers that can modulate transcription from endocrine promoters.
Dynamics of H3S28ph and H3S10ph in E12.5 multipotent progenitors
We next examined H3S28ph and H3S10ph in FACS sorted Egfp+ multipotent pancreatic pro-
genitors from pancreatic buds at an earlier E12.5 stage embryos of a Pdx1:Egfp genotype [62]
Msk Represses Pancreatic Beta Cell Fate
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Fig 1. A screen for histone modifications down stream of signaling pathways in E15.5 pancreatic epithelial
cells. (A) FACS scatter plots of cells treated with either IgG (control) or Onecut1 (Oc1+) antibody from Pdx1:Egfp
E15.5 pancreata. The FACS purified Oc1+ cells, both Pdx1-GFP+ (Oc1+P+) and Pdx1-GFP- (Oc1+P-), were used for
ChIP and qPCR (box labeled Oc+). The x and y axes indicate fluorescence intensity (F.I.). (B) RT-qPCR for ductal
transcripts Oc1 and Sox9 in Oc+ (green) and Oc- (blue) cells. (C-J) Patterns for indicated histone modifications at
select pancreatic genes (n = 3 technical replicates). Ins2 (Insulin2), Ins1 (Insulin1), Neurog3 (Neurogenin3) and Amyl
(Amylase2a). The y-axis shows enrichment over IgG. All P-values were calculated by Student’s t-test, one tailed.
doi:10.1371/journal.pone.0166703.g001
Msk Represses Pancreatic Beta Cell Fate
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(Figs 2A and S1D, n15 independent sorts). Since we dissected out the pancreatic buds, we
excluded Egfp+ cells from stomach or duodenum [24] in addition to excluding the Pdx1:Egfp
negative pancreatic mesenchymal cells by FACS [62], (Figs 2A and S1D). The isolated cells
constitute a majority of the pancreatic epithelial cells at E12.5. RT-qPCR showed marked
enrichment of the expected Pdx1, Oc1, Cpa1, Sox9, Neurog3 and Ptf1a transcripts, while Ins1,
Ins2, and Amyl were not expressed in the Pdx1:Egfp+population (S1E Fig), indicating the
majority of the isolated cells are multipotent pancreatic epithelial progenitors. A total of 20,000
FACS purified Pdx1:Egfp+ cells, pooled from multiple sorts, were used both for antigen and
IgG controls for each independent ChIP experiment.
H3S28ph showed significant enrichment at the Pdx1 promoter and at the Pdx1enh (Fig 2B,
n150 pancreata were pooled for each ChIP experiment, n = 3 biological and n = 3 technical
replicates for each experiment, P-value for Pdx1 promoter = 0.04 and for Pdx1enh = 0.045) in
E12.5 multipotent progenitors. The Ins1, Ins2, Neurog3 (endocrine) and Oc1 (ductal) promot-
ers did not show significant enrichment. The specific presence of H3S28ph at the Pdx1enh, pre-
viously implicated in beta-cell development [54–60], could reflect the activity of a chromatin
modifier important for beta cell specification.
The promoters for the acinar lineage specific Ptf1a and Amyl genes were also significantly
enriched for H3S28ph in E12.5 progenitors (Fig 2B, n150 pancreata were pooled for each
independent ChIP experiment, n = 3 biological replicates and n = 3 technical replicates for
each experiment, P-value for Ptf1a = 0.03 and for Amyl = 0.01). This is critical because Ptf1a is
a key specifier of the acinar lineage [27–29] and Amyl is a definitive marker of acinar cell
Table 1. Summary of histone modifications, corresponding signaling pathways, and enrichment found in this study at gene promoters.
Histone Modifications Signaling pathway Promoters Positive Promoters Negative
H3S28ph • MAPK
• Retinoic Acid
• PI3K
• TNF
• Jak-Stat
• cAMP/CREB [5, 9–20]
• Ins1
• Ins2
• Pdx1 enh
• Neurog3
• Amyl
• Onecut1
• Sox9
H3S10ph • MAPK
• Retinoic Acid
• PI3K
• TNF
• Jak-Stat
• cAMP/CREB [5,9–20]
• Ins1
• Ins2
• Pdx1 enh
• Neurog3
• Amyl
• Onecut1
• Sox9
H3K79me2 • Wnt
• Retinoic Acid
• Fgf [63, 64]
Onecut1
• Sox9
• Pdx1 enh
• Amyl
• Ins1
• Ins2
• Neurog3
H4R3me2 • BMP
• Jak-Stat
• Wnt
• RA [65–67]
• Ins1
• Ins2
• Pdx1enh
• Neurog3
• Amyl
• Sox9
• Onecut1
H3K18ac • PI3K [68] • Ins1
• Ins2
• Pdx1enh
• Neurog3
• Amyl
• Sox9
• Onecut1
doi:10.1371/journal.pone.0166703.t001
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differentiation, and the specific enrichment at these promoters could represent an important
step for modulating acinar differentiation. No gene promoters examined showed statistically
significant enrichment for H3S10ph (n150 pooled pancreata for each biological replicate,
n = 2 biological replicates, n = 3 technical replicates for each experiment; data not shown).
Altogether, the specific enrichment of H3S28ph at the endocrine and acinar lineage specific
genes, but not ductal genes, in E12.5 multipotent pancreatic progenitors and in E15.5 Oc1+
pancreatic epithelial cells (Fig 1) suggests that these chromatin modifications could specifically
modulate endocrine and acinar lineages during pancreatic development.
Enrichment patterns of the chromatin modifiers of H3S28ph: MSK1/2 in
E12.5 progenitors
Mitogen and Stress activated Kinases 1 and 2 (MSK/12) are the only known chromatin modifi-
ers of H3S28ph and H3S10ph [9–20]. Hence, we examined whether phosphorylated MSK1
and MSK2 would directly bind at the endocrine and acinar lineage specific genes, relating to
Fig 2. Dynamics of H3S28ph and the chromatin modifiers MSK1/2 in E12.5 FACS sorted cells. (A)
Representative plot showing FACS sorted cells from E12.5 Pdx1: Egfp pancreata. (B) ChIP qPCR analysis for
H3S28ph at select genes in E12.5 Pdx1: Egfp positive multipotent pancreatic progenitors, n150 pooled
pancreata were used for each biological replicate. P-values for H3S28ph enrichment over IgG were: Pdx1
promoter = 0.04, Pdx1enh = 0.045, Ptf1a = 0.03 and Amylase2a = 0.01, n = 3 biological replicates and n = 3
technical replicates for H3S28ph. Values are averages of three independent experiments ±standard error. No
significant enrichment could be found for H3S10ph at the select genes, with n = 2 biological replicates, n = 3
technical replicates of each biological replicate (data not shown). (C, D) ChIP-qPCR showing enrichment of
MSK1S360ph over IgG (C) and MSK2T586ph over IgG (D) at the designated promoters in E12.5 multipotent
pancreatic progenitors. P-values are 0.03, 0.007 respectively for Pdx1enh and Amyl promoter in E12.5 pancreatic
progenitors for MSK1ph and 0.04, 0.04 and 0.01 for Neurog3, Ptf1a and Ins2 respectively for MSK2ph, n150
pooled pancreata for each biological replicate at E12.5. Values are averages of two independent experiments
and 3 technical replicates ±standard error. Y-axis represents enrichment of H3S28ph, MSK1S360ph or
MSK2T586ph over IgG. All P-values were calculated with a paired Student’s t test in independent experiments;
* 0.05, ** 0.01, one tailed.
doi:10.1371/journal.pone.0166703.g002
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the enrichment of H3S28ph at both acinar and endocrine genes (Figs 1C and 2B). In E12.5
multipotent progenitors, we found significant enrichment of MSK1S360ph at the beta cell spe-
cific Pdx1enh, and enrichment of MSK2T586ph at the pan-endocrine Neurog3 promoter (Fig
2C and 2D, n150 pooled pancreata for each biological replicate, n = 2 biological and 3 techni-
cal replicates, P-values are 0.03 and 0.04 respectively). Conversely, significant binding was
detected at the Amyl promoter for MSK1S360ph and at the Ptf1a promoter for MSK2T586ph
(Fig 2C and 2D, n150 pooled pancreata for each biological replicate, n = 2 biological and 3
technical replicates, P-values are 0.007 and 0.04 respectively). None of the other promoters
examined showed significant binding. Altogether, these chromatin binding data suggest that
MSK1 and MSK2 isoforms could directly modulate endocrine and acinar differentiation.
Expression pattern of the MSK1 and MSK2 during pancreatic
development
MSK1Ser360ph (MSK1S360ph) and MSK2Thr586ph (MSK2T586ph) showed near ubiquitous
expression in the nuclei of all pancreatic epithelial cells at E15.5 and in adult pancreata (Figs 3A
and 3C–3F and S2A–S2D, n5 pancreata for each staining). The nuclear expression of MSK1/2
is consistent with their roles as chromatin modifiers (Fig 3A and 3C–3F). We further confirmed
that sparsely present endocrine cells also expressed MSK1S360ph and MSK2Thr586ph. Out of
all Ins1/2 positive cells counted, 74% of cells coexpressed MSK1S360ph (Fig 3C, arrows) and
87% of Neurog3 positive cells coexpressed MSK1S360ph (Fig 3C, arrowhead, n5 pancreata) at
E15.5. Similarly, 75% of all Ins1/2+ cells co-expressed MSK2T586ph (Fig 3D, n5 pancreata) at
E15.5. In the adult pancreata, both islets and exocrine tissues expressed MSK1S360ph and
MSK2T586ph (Fig 3E and 3F), with considerably higher levels of MSK1S360ph detected at the
outer edges of the islets, possibly in alpha cells (arrows, Fig 3E).
Pharmacological inhibition of the Chromatin modifier MSK1/2 using SB-
747651A
Next, we pharmacologically inhibited the MSK1/2 using SB-747651A, the best-available spe-
cific and potent ATP-competitive inhibitor of N-terminal kinase domain of MSK1/2 [69].
Other drugs such as H89 and Ro 31–8220 have been described before for pharmacological
inhibition of MSK proteins [9–20]. Naqvi et al. did a comparative study to analyze the inhibi-
tory effect of H89, Ro 31–8220 and SB747651A, against more than one hundred kinases. They
showed that SB747651A inhibits the activity of N-terminal kinase domain of MSK1 activity
potently, with 5% activity remaining, as opposed to H89, which has 25% MSK1 activity
remaining and Ro 31–8220 which has relatively many more off-targets. Even though we can-
not discount the possibility that SB-747651A may block other related AGC kinases, based on
the reagents available, this is the best method to temporally and spatially block MSK activity.
SB-747651A markedly reduced the evident levels of MSK1S360ph, confirming that it effec-
tively blocks the phosphorylation of the N-terminal domain of MSK1 (Fig 3A and 3B; n5
pancreata for each biological replicate, n = 2 biological replicates, [69]. An antibody against
the phosphorylated N-terminal domain of MSK2 is unavailable.
Next, we performed western blot to determine whether the levels of H3S28ph and H3S10ph
were altered upon SB-747651A treatment during pancreatic development. Upon SB-747651A
treatment, in E15.5 pancreatic explants for one day, the levels of H3S28ph were reduced by
about one third (Fig 3G–3I, n = 2 biological replicates), while H3S10ph levels remained unal-
tered (Fig 3H and 3J). The residual H3S28ph in SB-747651A treated explants could be from
cells undergoing mitosis, which remains unchanged between controls and inhibitor treated
pancreata (S6A–S6C Fig). Thus, SB-747651A impedes MSK mediated phosphorylation of
Msk Represses Pancreatic Beta Cell Fate
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Fig 3. MSK1/2 is expressed in the pancreatic epithelium and mediates phosphorylation of Histone H3
at Ser28. (A, B) Epifluoroscent images showing expression of MSK1S360ph and DAPI (inset) in pancreatic
sections from DMSO and SB-747541A treated explants at E15.5, cultured 4 days. DAPI stained images
(inset) were pseudo-colored white to enhance contrast. n5 pancreata for each staining. Scale bar = 12.5 μm.
(C-F) Expression of the indicated proteins in pancreatic sections from E15.5 stage (C, D) and (E, F) adult
islets. Arrows in panel C indicate co-expression of MSK1S360ph with Ins1/2 (red), arrowheads indicate
coexpression of MSK1S360ph with Neurog3 (blue). Arrows in panel E show high expression of MSK1S360ph
Msk Represses Pancreatic Beta Cell Fate
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histone H3S28, but not H3S10ph, in E15.5 pancreatic explants. In accord with SB-747651A
inhibiting MSK mediated phosphorylation of H3 at Ser28, we examined H3S28ph and
H3S10ph levels in Msk1; Msk2 double mutant pancreata. We found that H3S28ph, but not
H3S10ph, levels were significantly reduced in Msk1; Msk2 double mutants (S3A–S3D Fig).
This further confirms that MSK proteins mediates phosphorylation at histone H3 ser28 resi-
due during pancreatic development. However, Msk1-/- mutants showed much higher induc-
tion of H3S28ph, suggesting a compensatory mechanism (S3 Fig and Fig 3A–3D). MSK1/2 has
not been associated with histone modifications other than H3S28ph and H3S10ph [1].
SB-747651A treatment augments the endocrine lineage
To determine the consequences of MSK1/2 inhibition on different pancreatic lineages, we
treated E12.5 and E15.5 pancreatic explants with SB-747651A. To verify whether development
of all pancreatic lineages occurs normally in the explants, we examined select genes expressed
in different lineages through 4 days of explant culture. The genes specific for endocrine line-
ages, such as Ins1, Ins2 and Gcg, and specific for the acinar lineage, such as Amyl, showed a
steady increase over a period of 4 days of explant culture from E12.5 and E15.5 stages, similar
to normal pancreatic development, suggesting that whole pancreatic explant cultures are com-
patible with differentiation of all pancreatic lineages (S4A–S4D Fig, n10 pancreata for each
biological replicate, n = 2 biological and n = 3 technical replicates).
SB-747651A treatment for one day in E12.5 explants caused an increase in the transcript
levels of the endocrine progenitor marker Neurog3 by about 1.5 fold and its immediate down-
stream targets Insm1, Pax6, and Rfx6 by 2-fold (Fig 4A, P-values0.01, n10 pancreata each
for DMSO and SB-747651A treatment for each biological replicate, n = 2 biological and n = 3
technical replicates for each). Continued SB-747651A treatment for a total of 4 days resulted in
downregulation of Neurog3, Insm1, Pax6, and Rfx6 mRNAs (Fig 4A, P-value are 0.008, 0.02,
0.04, 0.1 respectively). The genes specific for the different endocrine lineages Gcg, Ins1, Ins2,
and Pdx1 were increased 3-fold, 4-fold, 10-fold, and 2-fold respectively on day 1 (Fig 4B, n10
pancreata each for DMSO and SB-747651A treatment and for each biological replicate, n = 2
biological and n = 3 technical replicates, all P-values0.01, respectively). In contrast to endo-
crine progenitor markers, the levels of endocrine differentiation genes Gcg, Ins1, Ins2, and
Pdx1 remained upregulated on day 4 of continuous inhibitor treatment (Fig 4B, n10 pan-
creata each for DMSO and SB-747651A treatment and for each biological replicate, P-value
are 0.01, 0.002, 0.05, 0.03, respectively). This suggests that at the E12.5 stage, there are limited
number of competent pancreatic progenitors that can differentiate towards Neurog3 positive
endocrine lineages. These limited number of Neurog3 positive pancreatic progenitors are
exhausted and precociously differentiate towards specific endocrine lineages upon SB-
747651A treatment. MafA, a mature beta cell differentiation marker, showed about 10-fold
enrichment upon continuous SB-747651A treatment for 4 days (Fig 4B, n10 pancreata each
for DMSO and SB-747651A treatment and, n = 2 biological and n = 3 technical replicates for
each biological replicate P-value = 0.01). Together, these data indicate that prolonged treat-
ment with SB-747651A enhances endocrine differentiation in E12.5 explants (Fig 4B).
Next, immunohistochemistry was performed to determine if the above-mentioned changes
in transcript levels in the E12.5 explants were due to increased numbers of endocrine cells. A
at the exterior edge of the islet, possibly alpha cells. n5 pancreata for each staining, Scale bar for panel
C = 12.5μm and for panel D-F = 50μm. (G, H) Western Blot for H3S28ph and H3S10ph in DMSO and SB-
747541A treated explants, vinculin is the loading control, n = 2 biological replicates. (I, J) Quantification of the
blots corresponding to panels G and H from two biological replicates.
doi:10.1371/journal.pone.0166703.g003
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more than 2-fold increase in the overall glucagon expression domain was observed at day 1 of
culture (Fig 4C–4E, P-value = 0.001, n5 pancreata for each biological replicate and for each
condition, DMSO and SB-747651A treatment, n = 2 biological replicates) and also on day 4 of
culture (Fig 4F–4H, P-value0.0001, n5 pancreata for each biological replicate and for each
condition, DMSO and SB-747651A treatment, n = 2 biological replicates). Additionally, cells
expressing lower levels of Glucagon (indicated by arrows, Fig 4D and 4G), in addition to nor-
mal bright Glucagon cells, were observed upon SB-747651A treatment. These cells could not
Fig 4. SB-747651A treatment causes increased differentiation of E12.5 pancreatic progenitors towards the
endocrine lineage. (A) RT-qPCR analysis of indicated endocrine progenitor genes on day 1 (blue) and day 4 (green) of
SB-747651A treatment in pancreatic explants from E12.5. Y-axis shows normalized enrichment in SB-747651A treated
relative to DMSO controls. The P-values for day1 are0.01 for all genes examined, for day4 are 0.008, 0.02, 0.04, 0.1
respectively for Neurog3, Insm1, Pax6, and Rfx6. n10 pancreata were pooled for each RT-qPCR experiment for DMSO
and SB-747651A treatment and for each biological replicate, n = 2 biological and n = 3 technical replicates for each. (B)
RT-qPCR analysis of indicated endocrine differentiation genes on day 1 (blue) and day 4 (green) of SB-747651A treatment
in pancreatic explants from E12.5. Y-axis shows normalized enrichment in SB-747651A treated explants relative to
DMSO controls. The P-values for day1 are0.01 and for day4 are 0.01, 0.002, 0.05, 0.03 for Gcg, Ins1, Ins2, and Pdx1
respectively. n10 pancreata were pooled for each RT-qPCR experiment for DMSO and SB-747651A treatment and
for each biological replicate, n = 2 biological and n = 3 technical replicates for each. (C-H) Immunohistochemistry and
quantification of Glucagon positive domain in pancreatic sections upon one day (C-E, P-value = 0.001) and 4 days of SB-
747651A treatment (F-H, P-value0.0001), n5 pancreata were analyzed for immunohistochemistry for each biological
replicate and for each condition, DMSO and SB-747651A treatment. n = 2 biological replicates Scale bar = 50μm. The
panels C and D were exposed to reveal cells expressing lower levels of Gcg. (I-K) Immunohistochemistry and quantification
of Insulin1/2 positive domain in pancreatic sections upon SB-747651A treatment on day4 at E12.5 stage, P-value, 0.005,
n5 pancreata for each biological replicate and for each condition, DMSO and SB-747651A treatment. n = 2 biological
replicates, scale bar = 25μm. Insets on panels I and J shows magnified views to highlight cytoplasmic staining of Ins1/2. All
area measurements were done relative to the total pancreatic area per section. Arrows in D, G show low level expression of
Glucagon in explants treated with SB-747651A treatment. Values are averages of 3 independent experiments ± standard
error unless otherwise stated. All P-values were calculated by Student’s t test, comparing DMSO and SB-747651A treated
samples in independent experiments, * 0.05, ** 0.01, ***0.001, two-tailed.
doi:10.1371/journal.pone.0166703.g004
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be visualized in DMSO controls (compare Fig 4 panels C and D and Fig 4 panels F and G).
The beta-cell expression domain indicated by Insulin1/2 increased by 2.3 fold upon SB-
747651A treatment on day 4, with individual cells appearing equally bright in SB-747651A
treatment versus DMSO controls (Fig 4I–4K, P-value, 0.005, n5 pancreata for each biological
replicate and for each condition, DMSO and SB-747651A treatment, n = 2 biological repli-
cates). We conclude that SB-747651A treatment causes increased differentiation of E12.5 pro-
genitors towards the endocrine lineage.
SB-747651A treatment on explants harvested at the E15.5 stage led to more robust increases
in endocrine lineage and beta cell specific transcripts. Neurog3 transcripts were enriched 1.7
fold on day 1 (Fig 5A, n10 pancreata each for DMSO and SB-747651A treatment and for
each biological replicate, n = 2 biological replicates, P-values = 0.03 for day 1). Immunohis-
tochemistry revealed 2-fold more Neurog3 positive cells upon SB-747651A treatment, as com-
pared to controls on day 1 (n5 pancreata for each biological replicate and for each condition,
DMSO and SB-747651A treatment, n = 2 biological replicates, P-value = 0.008, arrowheads,
Fig 5B and 5C and S5A–S5F Fig). The Neurog3 transcripts returned to wild type levels on days
4 and 8 (Fig 5A). More strikingly, the immediate downstream targets of Neurog3, such as
Insm1, Pax6, and Rfx6, were enriched on days 1, 4, and 8 by 4–8 fold (Fig 5A, n10 pancreata
each for DMSO and SB-747651A treatment and for each biological replicate, n = 2 biological
replicates, P-values0.01).
The genes expressed in specific endocrine lineages such as Ins1, Ins2, and Gcg transcripts
increased by 3–5 fold on day 1 (Fig 5D, n10 pancreata for each biological replicate for
DMSO and SB-747651A treatment, n = 2 biological replicates, all P-values0.001), rising to
16–33 fold on day 4 (Fig 5D, n10 pancreata for each biological replicate for DMSO and SB-
747651A treatment, n = 2 biological replicates, all P-values0.01) and 86–163 fold on day 8 of
SB-747651A treatment in E15.5 explants (Fig 5D, n10 pancreata for each biological replicate
for DMSO and SB-747651A treatment, n = 2 biological replicates, all P-values0.01). The
Ins1, Ins2, and Gcg transcripts were 2.5, 5.2, and 2.3 fold more induced, respectively, upon SB-
747651A treatment at E15.5 than at E12.5 (S4E–S4J Fig), consistent with the later-born (E15.5)
pancreatic progenitors gaining competence to generate more beta cells, agreeing with previous
studies [51]. Mature beta cell genes including MafA increased by 120 fold on day 4 (P-
value = 0.01), while Glucose Transporter2 (Glut2) and Proconvertase1 (Pcsk1), genes associated
with glucose transport and insulin processing increased by about 5-fold and by ~8 fold in SB-
747651A treated explants at days 4 and 8 of explant culture from E15.5 (Fig 5D, n10 pan-
creata each for DMSO and SB-747651A treatment and for each biological replicate, n = 2 bio-
logical replicates, P-values less than 0.01 for Glut2 and Pcsk1). Altogether, these data indicate
that SB-747651A treatment dramatically augments the expression of beta cell specific genes at
E15.5.
Consistent with changes in transcript patterns, immunofluorescence showed a remarkable
5-fold increase in the expression domains of double positive Ins1/2+; Pdx1:Egfp+ cells (Fig
5E–5K, P-value = 3.12×10−7, n5 pancreata for each biological replicate for DMSO and SB-
747651A treatment, n = 3 biological replicates) and more than a 3-fold increase in Pdx1:Egfp+;
Ins1/2- cells, in SB-747651A treated E15.5 pancreatic explants on day 4 (P-value = 5.6×10−5,
Fig 5E–5K, n = 3 biological replicates). Extensive co-localization was observed between Pdx1
protein levels and Insulin1/2 at E15.5 stage of pancreatic development (S2G and S2H Fig.
Next, we determined the overall levels of processed form of Insulin by an ELISA assay. The
ELISA assay revealed more than 2-fold elevation in processed Insulin levels in lysates from
pancreas treated with SB-747541A for 4 days (Fig 5L, P-value = 0.003). Altogether, these data
indicate SB747541A treatment causes marked increase in the production of Insulin in pancre-
atic explants.
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Fig 5. Pancreatic beta cell fate is markedly increased by SB-747651A treatment at E15.5. (A) Expression levels of indicated
endocrine progenitor genes on days 1, 4, and 8 of SB-747651A treatment in explants harvested from E15.5 stage. Y-axis shows
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Next, we performed co-immunohistochemical staining for both Insulin and Glucagon by a
method that ensures minimal cross-reactivity between antibodies (See Materials and Meth-
ods). This is important because Ins1/2;Gcg double positive cells arise during early pancreatic
development and do not contribute to mature islets [50]. Ins1/2+;Gcg- were induced 4-fold
(Fig 6A–6C, P-value = 4×10−4 and S2 M-T, n = 3 biological replicates) and Gcg+;Ins1/2- were
induced about 2.2 fold (Fig 6A–6C, P-value = 0.02) upon SB-747651A treatment, while Ins1/2+;
Gcg+ double positive cells remained the same as the controls (Fig 6A–6C, P-value = 0.3). Alto-
gether, our data indicate that inhibition of MSK1/2 using SB-747651A drug markedly promotes
the differentiation of alpha and beta cells independently without any co-induction of Ins1/2 and
glucagon. This suggests that SB-747651A treatment induces mature alpha and beta cells that
contribute to adult islets, as suggested by lineage tracing studies of Herrera 2000 [50], instead of
double positive Ins+;Gcg+ cells that do not contribute to adult islets.
Next, we examined MafA, a mature beta-cell marker by immunofluoroscence to confirm
our previous observation that continuous SB-747541A treatment for 4 days in E15.5 explants
causes nearly 100-fold increase in the MafA transcripts (Fig 5D). Immunofluorescence
revealed nearly 10-fold increase in the number of MafA cells upon SB-747541A treatment
compared to DMSO controls (Fig 6D–6H, P-value = 0.003, n = 4 independent pancreata) con-
firming that the number of cells expressing MafA were elevated in these conditions.
The acinar lineage is diminished upon SB-747651A treatment
In contrast to the endocrine lineage, the acinar lineage was severely depleted upon continued
SB-747651A treatment. After a slight induction on day 1, exocrine genes such as Ptf1a, Amyl,
Nr5a2, Gata4, and Mst1 were drastically reduced by 3125, 5263, 1.2, 1.4, and 3.3 fold, respec-
tively, upon SB-747651A treatment for 4 days in E12.5 explants (Fig 7A, n10 pancreata each
for DMSO and SB-747651A treatment and for each biological replicate, P-values0.01 for
Ptf1a and Amyl, n = 3 biological and 3 technical replicates). SB-747651A treatment in E15.5
explants led to corresponding 15, 100, 1.7, 1.5, and 6.7 fold reductions at day 4 and 43, 204,
2.3, 1.9, and 2.7 fold reductions, respectively, at day 8 of culture for Ptf1a, Amyl, Nr5a2, Gata4,
and Mst1 respectively (Fig 7B, n10 pancreata for each biological replicate for DMSO and SB-
747651A treatment, P-values0.01 for Ptf1a and Amyl, unless otherwise indicated on the
graphs, n = 3 biological and 3 technical replicates). Note that the maximum fold decrease was
found for Ptf1a and Amyl, but not for Nr5a1, Gata4 and Mst1, suggesting that response ele-
ments in the Ptf1a and Amyl genes are most sensitive to SB-747651A treatment.
relative fold change in DMSO controls and SB-747651A treated explants. n10 pancreata were pooled for both DMSO and SB-
747651A treated explants for each biological replicate, n = 2 biological replicates. P-values for Neurog3, day 1 = 0.03 and for Insm1,
Pax6, and Rfx6 were0.01 for both days 4 and 8. (B, C) Immunohistochemistry on pancreatic sections from E15.5 explants cultured
for one day in DMSO or SB-747651A showing expression of Amyl and Neurog3. n5 pancreata for each biological replicate and for
each condition, DMSO and SB-747651A, n = 2 biological replicates, P-value = 0.008. Amylase is pseudo-colored white to enhance
contrast. (D) Expression levels of indicated endocrine differentiation and indicated mature genes in E15.5 stage explants cultured for 1,
4, and 8 days. Y-axis shows relative fold change in DMSO and SB-747651A treated explants. The color scheme for the bar graphs is
displayed in the figure. n10 pancreata were pooled each for DMSO and SB-747651A treatment for each biological replicate, n = 2
biological replicates. P-values for Ins1, Ins2, and Gcg on day1 are0.001,0.01 for day 4 and0.01 for day 8, P-value0.01 for
MafA, Glut2 and Pcsk1 on days 4 and 8. (E-K) Expression and quantification of Insulin1/2 visualized by immunohistochemistry on
pancreatic sections from Pdx1:Egfp pancreata, obtained from E15.5 stage, cultured for 4 days in DMSO or SB-747651A. P-
values = 3.12×10−7 for Pdx1:Egfp+; Ins1+ and 5.6×10−5 for Pdx1:Egfp+; Ins1- on panel H, n5 pancreata each for DMSO and SB-
747651A treatment and for each biological replicate, n = 3 biological replicates. Scale bar on all panels = 25μm. Values are averages of
independent experiments ± standard error unless otherwise stated. (L) Insulin quantification by ELISA in pancreatic lysates treated
with DMSO or SB-747541A for 1 or 4 days. All P-values were calculated by Student’s t test, comparing DMSO and SB-747651A
treated samples in 3 independent experiments, * 0.05, ** 0.01, ***0.001, two-tailed. All RT-qPCR values are normalized to
beta-actin.
doi:10.1371/journal.pone.0166703.g005
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Consistent with the changes in the transcript levels, Amylase protein levels were substan-
tially reduced in explants from E12.5 and E15.5 stages that were cultured for 4 days (Fig 7C–
7F, n5 pancreata for each biological replicate for DMSO and SB-747651A treatment and,
n = 2 biological replicates). The E12.5 stage is associated with the initiation of acinar differenti-
ation, while significant acinar differentiation has occurred by the E15.5 stage, suggesting that
MSK1/2 contributes to both specification and maintenance of acinar fates.
To determine whether newly recruited endocrine cells are induced within the peripheral
acinar domain at E15.5 upon SB-747651A treatment, we examined the expression of Neurog3
and Amyl on day 1 in SB-747651A treatment explants. We considered this because the Amyl
positive acinar domain is evident on day 1 of SB-747651A treatment as opposed to day 4 when
acinar domain is essentially lost (Fig 7A and 7B, day 1). Any co-induction of Neurog3 with
Amyl would potentially indicate trans-differentiation of acinar cells into endocrine lineage.
Fig 6. Expression analysis of Ins1/2; Gcg and MafA upon SB-747541A treatment. (A-C) Co-expression and
quantification of Ins1/2 and Gcg expression domains by immunohistochemistry on pancreatic sections from E15.5
stage explants cultured for 4 days in DMSO or SB747541A. P-values = 4×10−4 for Ins1/2+;Gcg- and 0.02 for Gcg+;
Ins1/2-, n5 pancreata each for DMSO and SB-747651A treatment and for each biological replicate, n = 3 biological
replicates. (D-H) Expression and quantification of MafA positive cells in pancreatic explants treated with DMSO
(D, F) and SB-747541A (E, G) for 4 days. Scale bar on all panels = 25μm. Values are averages of 2 independent
experiments ± standard error unless otherwise stated. All P-values were calculated by Student’s t test, comparing
DMSO and SB-747651A treated samples in 2 independent experiments, * 0.05, ** 0.01, ***0.001, two-tailed.
doi:10.1371/journal.pone.0166703.g006
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Fig 7. Acinar fates are markedly depleted upon SB-747651A treatment. (A) Expression levels of indicated
acinar and duct genes upon culture of E12.5 explants for 1 and 4 days. Y-axis shows relative fold change in DMSO
controls and upon SB-747651A treatment. P-values0.01 for both Ptf1a and Amyl for day 4, n = 3 biological and 3
technical replicates. (B) Expression levels of indicated acinar and duct genes upon culture of E15.5 explants for 1 day,
4 days, and 8 days on explants treated with DMSO or SB-747651A (n = 3 independent replicates). Y-axis shows
relative fold change in DMSO controls and upon SB-747651A treatment. Color scheme for the bar graphs is displayed
in the figure. n10 pancreata for each each biological replicate for DMSO and SB-747651A treatment, P-values
0.01 for Ptf1a and Amyl for day 4 and day8, n = 3 biological and 3 technical replicates. (C-F) Immunohistochemistry
showing Amyl expression on pancreatic sections from E12.5 (C, D, scale bar = 50μm) and E15.5 (E, F, scale
bar = 50μm) stages harvested at 4 days of culture. n5 pancreata for each biological replicate for DMSO and SB-
747651A treatment n = 2 biological replicates. (G, H) Oc1 expression in sections from pancreatic explants from E15.5
stage (scale bar = 100μm, G, H) from DMSO or SB-747651A treated explants, harvested at 4 days of culture. Insets
shows pseudo-colored DAPI staining. Values are averages of independent experiments ± standard error unless
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However, we did not detect any co-expression between Amyl and Neurog3 on day 1 of SB-
747651A treatment (Fig 5B and 5C and S5A–S5F Fig) suggesting that SB-747651A -induced
endocrine cells may not be arising within the peripheral acinar domain at E15.5. More detailed
lineage tracing studies would further resolve this.
The trunk and future duct markers Oc1 and Sox9 were slightly induced upon SB-747651A
treatment at E12.5 and E15.5, but returned to wild type levels upon continuous culture in SB-
747651A (Fig 7A and 7B). Immunohistochemistry also did not reveal changes in the Oc1
expression domain upon SB-747651A treatment in E15.5 explants (Fig 7G and 7H). In conclu-
sion, SB-747651A treatment significantly depletes the acinar lineage without affecting duct
fates.
SB-747651A treatment does not lead to significant changes in cell
proliferation or apoptosis
To investigate whether increased proliferation contributes to enhanced specification of endo-
crine cells upon SB-747651A treatment, we administered BrdU on E15.5 explants for 8 hrs on
day 1 and examined the explants after 2 days. Quantification of the number of BrdU positive
nuclei, normalized to total explant surface area, showed no change between DMSO controls
and SB-747651A treated cells indicating that no net gain in proliferation contributes to
increased endocrine expression domain (S6A–S6C Fig, P-value = 0.37, n7 pancreata each for
DMSO and SB-747651A treatment and for each biological replicate, n = 2 biological replicates)
Next, we examined apoptosis in SB-747651A treated explants using two independent meth-
ods: Cleaved Caspase3 and Tunel staining. We did not find significant changes in the number
or location of cleaved caspase3 or TUNEL positive cells in SB-747651A treated explants, on
either day 1 (S6D–S6I Fig) or day 4 (S6J–S6O Fig), n7 pancreata each for DMSO and SB-
747651A treatment and for each biological replicate, n = 2 biological replicates) of explant cul-
tures, indicating that depletion of acinar fates observed upon SB-747651A treatment may not
be attributable to apoptosis.
Repression of endocrine fates by MSK1/2 is independent of intercellular
interactions in the explants
To determine whether the observed enhancement of endocrine differentiation upon SB-
747651A treatment is an indirect consequence of reduced acinar differentiation in the explants
due to intercellular interactions, we set up dilute cultures of completely dissociated and FACS-
isolated pancreatic epithelial cells, plated at a sub-clonal density of 2000–3000 cells/ 2 cm2,.
Representative images illustrating well-separated single cells on day 1 of culture are shown in
S2–S2L Fig. We sorted for DBA, a cell surface antigen expressed on the duct cells [70, 71] and
Egfp in Pdx1:Egfppositive pancreata (Fig 8A and S7A Fig). We found that the enrichment pro-
files of genes examined in this study for the different cell subpopulations remained similar
upon 3 days of culture on OP9 feeder cells ([71], S7B and S7C Fig).
The following four populations were parsed out using FACS (Fig 8A and 8B and S7A Fig,
n25 pooled pancreata for each biological replicate, n = 2 biological and 3 technical repli-
cates): DBA+; Pdx1:Egfp- duct progenitors [71], DBA+;Pdx1:Egfp+, a mix of duct and endo-
crine progenitors (S7B and S7C Fig, Oc1+, Neurog3+, Pdx1+), DBA-;Pdx1:Egfpmed, a mix of
otherwise stated. All P-values were calculated by Student’s t test, comparing DMSO and SB-747651A treated
samples in independent experiments, *0.05, **0.01, ***0.001, two-tailed.
doi:10.1371/journal.pone.0166703.g007
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Fig 8. Enhancement of endocrine genes upon SB-747541A treatment is independent of intercellular interactions.
(A) Scatter plos of cells from E15.5 pancreata, sorted by FACS into Egfp and rhodamine conjugated DBA positive cells. (B)
Hierarchy of different lineages during pancreatic development indicating expression of DBA and Pdx1-Egfp. (C-F)
Normalized expression of indicated genes on third day of culture of different FACS sorted populations treated with either
DMSO or SB-747651A. n25 pooled pancreata for each biological replicate, n = 2 biological and 3 technical replicates, P-
values = 0.01 for Gcg in DBA-;Pdx1:Egfpmed, 0.01 and 0.009, respectively for Ins1 and Ins2, in DBA-;Pdx1:Egfphigh cell sub-
population. Values are averages of independent experiments ±standard error unless otherwise stated. All P-values were
calculated by Student’s t test, comparing DMSO and SB-747651A treated samples in independent experiments, *0.05,
**0.01, ***0.001, two-tailed.
doi:10.1371/journal.pone.0166703.g008
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duct, alpha cell, and endocrine progenitors (S7B and S7C Fig, Oc1+, Gcg+, Neurog3+) and
DBA-;Pdx1:Egfphigh, a mix of beta and acinar cell precursors (S7B and S7C Fig, Ins1+, Ins2+,
Amyl+). It is not clear why DBA+; Pdx1:Egfp- cells aren’t as enriched for Oc1 as the double
positive DBA+; Pdx1:Egfp+ population. Prior studies have shown that Oc1 is co-expressed
with a subset of Neurog3 positive cells in the trunk domain at E15.5, explaining its enrichment
in the DBA+;Pdx1:Egfp+ and DBA-;Pdx1:Egfpmed populations (S7B and S7C Fig, 42].
The alpha cell specific Gcg transcripts were maximally upregulated upon SB-747651A treat-
ment in DBA-;Pdx1:Egfpmed cells (Fig 8C, P-value = 0.01) while the beta cell specific Ins1 and
Ins2 transcripts were induced maximally from DBA-; Pdx1: Egfphigh cells upon SB-747651A
treatment (Fig 8D and 8E, P-value = 0.01, 0.009 respectively, n25 pooled pancreata for each
biological replicate, n = 2 biological and 3 technical replicates). The DBA+;Pdx1:Egfp+ double
positive population and DBA+; Pdx1:Egfp- cells showed a modest induction of endocrine hor-
mones. Altogether, these data indicate that activation of endocrine genes upon SB-747651A
treatment is independent of intercellular interactions.
MSK1 and MSK2 proteins have distinct roles during pancreatic
development
To assess whether genetic ablation of MSK1/2 may agree with pharmacological inhibition, we
analyzed pancreata of germline Msk1 and Msk2 knockouts at E15.5 [9–12]. According to our
previous observations (Figs 4, 5, 6 and 7), inhibition by SB-747541A at E15.5 stage yielded
most robust increases in endocrine cell specification. Hence, this stage was chosen for further
analysis of Msk1/2 mutants. Compared to the wild type, an increase in total alpha cell mass was
observed in all of the genotypes examined (Fig 9A–9C and 9J and S8A–S8E and S8U Fig). The
increases in alpha cell mass were 1.6 fold for Msk1+/- (Fig 9A, 9B and 9J and S8A, S8B and
S8U Fig, P-value = 0.02), 2.6 fold for Msk1-/- (S8C and S8U Fig, P-value = 3.3x10-7), 1.9 fold
for Msk2+/- (S8D and S8U Fig, P-value = 2.2x10-4), 1.7 fold for Msk2-/- (Figs 9J and S9D, P-
value = 0.02), 2.1 fold for Msk1+/-; Msk2+/- (S8U Fig, P-value = 2.2x10-6 and S9D Fig), and 2.5
fold for Msk1-/-;Msk2-/- (Fig 9C and 9J and S8E and S8U Fig, P-value = 3.1x10-5). Notably, the
fold increase in alpha cell mass in Msk knockouts are similar to the ones obtained upon SB-
747651A treatment in E12.5 explants (Fig 4C–4H). We did not observe any overall changes in
the pancreatic size at this stage of development.
In Msk1+/- pancreata, a 1.6 fold increase in beta cell mass was observed (Fig 9D, 9E and 9K
and S8F, S8G and S8V Fig, P-value = 1.5x10-5), while other genotypes had only a nominal
increases in beta cell mass (Fig 9K and S8H–S8J and S8V Fig). These observations indicate
that knockout of both Msk1 and Msk2 promotes specification of alpha cell fates while only
monoallelic loss of Msk1 promotes beta cell mass. A conditional knockout of Msk isoforms in
the pancreas at E15.5 stage would be useful in resolving the differences observed in beta-cell
induction in SB-474541A treated pancreatic explants at E15.5 (about 6-fold) versus global Msk
knockouts (Compare Figs 5K and 9K).
Conversely, for acinar differentiation, Msk2 heterozygous, Msk2 homozygotes, and Msk1-/-;
Msk2-/- double mutant pancreata showed significantly reduced Amylase positive expression
domains (Fig 9G–9I and 9L, S8K, S8N, S8O, S8W and S9F Figs, P-value = 3.3x10-13, 0.004,
1.7 x10-6 for Msk2+/-, Msk2 homozygotes, Msk1-/-;Msk2-/- double mutant pancreata) while
Msk1 heterozygous or homozygous mutants did not show significant changes in the Amylase
domain (S8K–S8M and S8W Fig). In addition, the intensity of the Amylase expression
showed a considerable reduction in the Msk1; Msk2 double mutant pancreata. These results
suggest that both Msk1 and Msk2 function redundantly in stimulating acinar specification,
with the Msk2 isoform playing a more dominant role during acinar differentiation.
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Fig 9. MSK1 and MSK2 proteins have distinct functions during pancreatic development. (A-I) Representative images
showing expression of Glucagon (A-C, scale bar = 50μm), Insulin (D-F, scale bar = 50μm) and Amylase (G-I, scale bar =
100μm,) in the indicated genotypes at E15.5. (J-L) Glucagon, Insulin, and Amylase positive areas normalized to total area in the
indicated genotypes at E15.5. For Gcg, P-values are 0.01 for Msk1+/-, 3.3x10-7 for Msk1-/-, 2.2x10-4 for Msk2+/-, 0.02 for
Msk2-/-, 2.2x10-6 for Msk1+/-; Msk2+/- and 3.1x10-5 for Msk1-/-;Msk2-/-. For Ins1, P-value = 1.5x10-5 for Msk1+/-. For Amyl,
P-values are 3.3x10-13 for Msk2+/-, 0.004 for Msk1+/-; Msk2+/-, 1.7 x10-6 for Msk1-/-;Msk2-/-. Average number of sections/
pancreas for Ins1 and Gcg respectively were 17, 9.8 (wild type), 17.83, 5.6 (Msk1+/-), 15.6, 5 (Msk1-/-), 16.3, 5 (Msk2-/-), 14.75,
6.375 (Msk2+/-), 13, 13.5 (Msk1+/-; Msk2+/-), 15.12, 6.75 (Msk1-/-; Msk2-/-). All P-values were calculated by Student’s t test,
relative to wild type controls, *0.05, **0.01, ***0.001, two-tailed unequal variance, two-tailed. Values are averages of
independent experiments ± standard error unless otherwise stated.
doi:10.1371/journal.pone.0166703.g009
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Discussion
In this study, we uncovered a novel function for the chromatin modifier, MSK1/2, in suppress-
ing endocrine and promoting acinar differentiation during pancreatic development. We initi-
ated this study by performing a screen for signaling-dependent histone modifications at
sentinel pancreatic genes in FACS-enriched cell subpopulations. The screen led us to examine
the dynamics of H3S28ph in progenitors isolated at different developmental stages. We identi-
fied an enrichment of H3S28ph, which can be induced by MAPK, RA, PI3K, TNF, Jak-Stat, or
cAMP/CREB signaling pathways in different cellular contexts (Table 1), at endocrine and aci-
nar lineage-specific genes in the multipotent pancreatic progenitors, before the cells’ overt dif-
ferentiation into respective lineages. Both the Pdx1 promoter and Pdx1enh, and acinar specific
Ptf1a and Amyl gene promoters are pre-marked with H3S28ph in E12.5 progenitors. These
data indicate that before the overt differentiation of multipotent progenitors to different pan-
creatic lineages, the endocrine and the acinar genes are pre-marked with H3S28ph in the pro-
genitors. This may relate to the developmental competence of the progenitors as it might set
up these loci for further activation or repression [2, 7] depending on whether H3S28ph associ-
ated proteins are transcriptional activators or repressors at a given loci [19, 20]. To further
resolve this, we inhibited the corresponding chromatin modifier of H3S28ph during pancre-
atic development, MSK1/2.
Inhibition of the chromatin modifier for H3S28ph, MSK1/2, using SB-747541A, caused
more frequent differentiation towards the endocrine fate, while acinar differentiation is sup-
pressed. Inhibition of MSK1/2 led to the induction of Insulin1 and Insulin2 transcripts by 160-
and 140-fold, respectively, and Glucagon transcripts by 85-fold on day 8 in E15.5 explants. A
striking 5-fold increase was observed in the expression domain of Ins1 positive cells in E15.5
SB-747651A treated explants. In contrast, the acinar transcripts Ptf1a and Amyl and the Amyl
positive expression domain are severely depleted upon SB-747651A treatment at both E12.5
and E15.5. These data indicate that the normal function of MSK1/2 proteins would be to estab-
lish transcriptional activation of acinar genes such as Ptf1a and Amylase2a while repressing
endocrine progenitor genes such as Neurog3, Insm1, Pax6, and Rfx6.
Considering a near ubiquitous expression of both MSK1ph and MSK2ph in the pancreatic
epithelia, these data would suggest that MSK proteins normally induce acinar differentiation
of the pancreatic progenitors unless they get inhibited, perhaps by other signaling pathways.
The pathways that inhibit MSK activity to allow sparse induction of endocrine genes would
require future experimentation. Alternatively, MSK proteins could act as repressors of endo-
crine genes, along with other transcriptional regulators, to fine-tune expression in the progeni-
tors. Future studies would explore the mechanisms that underlie these effects. We also
carefully examined whether Ins1/2 and Gcg where co-induced upon SB-747541A treatment to
determine if we might be expanding an embryonic pool of double positive Ins1/2-Gcg cells.
We did not observe a significant expansion of the double positive Ins1/2-Gcg cells. Germline
knockout of MSK1 and MSK2 expanded alpha cell mass, while the Amyl positive acinar
domain was reduced. The observation of enhanced alpha cell production in the germline
MSK1/2 knockout is consistent with alpha cells being the preferential endocrine fate during
the initial stages of endocrine differentiation [51]. A conditional knockout of Msk1/2 in the
pancreas at the onset of secondary transition would be most critical to define its role specifi-
cally during beta cell differentiation. Altogether, the data indicate that inhibition or knockout
of MSK proteins causes more frequent differentiation to Neurog3 positive endocrine progeni-
tors, leading to an increase in the domain of endocrine cell types while differentiation towards
the acinar lineage is suppressed.
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A direct role of MSK1S360ph and MSK2T586ph proteins in modulating the endocrine and
acinar cell fate choices was implied by MSK1S360ph and MSK2T586ph binding to the
H3S28ph enriched promoters for Amyl and Ptf1a, and the Pdx1enh in E12.5 multipotent pro-
genitors. The presence of both H3S28ph and MSK proteins on both endocrine and acinar
genes and the contrasting effects of SB-747651A treatment on acinar and endocrine genes
indicate that MSK mediated H3S28ph may not be simply correlated with the transcriptional
status of the genes during pancreatic development. This is similar to other studies where MSK
mediated H3S28ph modification directs both positive and negative influences on the gene
expression (See Introduction for References).
We suggest that SB-747651A treatment of pancreatic progenitors arising from embryonic
stem cells could be used to enhance the production of beta cells for type I diabetic patients.
Our approach, to assess chromatin state dynamics at different developmental stages, proved
useful in identifying a drug-targetable step to enhance beta cell development. Similar
approaches, e.g. starting with the substrates in Table 1, could be used in other developmental
and stem cell differentiation contexts to enhance the production of desired cell fates.
Materials and Methods
Immunostaining of single cell suspensions for FACS sorting
Pancreata from 20–25 mice were dissected from E15.5 Pdx1:Egfp embryos at a given time and
treated with 0.25% trypsin for 7–10 min to generate single cell suspensions, washed 3X in 10%
serum + PBS, and fixed in Media A, with 2–3% formaldehyde (Invitrogen Cell and Perm kit)
for 10 minutes at RT (100 μl for 106 cells). Formaldehyde was quenched with 1 M glycine for 5
min followed by 3X washes with PBS. Non-specific binding of antibodies was blocked by 10%
FBS + PBS for 1 hr. Cells were subsequently resuspended in permeabilization media B (100 μl
for 106 cells) and incubated with primary antibody (2 μg/ml) for Oc1 for 1 hr at room tempera-
ture. One tenth of the cell suspension was set aside for incubation with same concentration of
rabbit IgG (2 μg/ml). Cells incubated with Oc1 and IgG antibody were washed 3x with PBS
+10% FBS for 10 min at RT. Both Oc1 and IgG treated cells were incubated with fluorophore
conjugated secondary antibody (7.5 μgm/ml), lacking the Fc domain, in permeabilization
media B for 1 hr. Cells were washed 3x with PBS for 10 min at RT and stored at 4˚C until
FACS the next day. To collect a sufficient number of cells from the E12.5 embryonic stage, 3–4
week old C3H/B6 hybrid female mice were superovulated by intraperitoneal injection of
PMSG (Sigma, 5 IU/mouse), followed 2 days later by HCG injection (Sigma, 5 IU/mice). The
mice were immediately bred with Pdx1:Egfphomozygous males. Pancreata were harvested
from E12.5 embryos and treated with 0.05% trypsin for 5 min at 37˚C, followed by three
washes in 10% serum + PBS, fixed with Media A (Invitrogen Cell and Perm kit) for 10 min at
RT, quenched with 1 M glycine for 5 min at RT (as before), washed 3x with PBS, and FACS
sorted for Egfp the same day.
FACS and RT-qPCR analysis
Cells positive for EGFP (E12.5), Oc1 (E15.5), and DBA (E15.5) were sorted from Pdx1:Egfp
embryos at low pressure on a 206 Diva FACS sorting machine into 1.5 ml Eppendorf tubes
containing 50 μl serum. The sorting was done relative to either Pdx1:Egfpnegative cells (E12.5)
or IgG (E15.5). Cells immunostained for Oc1 in a Pdx1:Egfpbackground was sorted into two
populations: Oc and Oc+. After FACS sorting, an aliquot of 5000 cells was kept for RNA analy-
sis and the rest for chromatin studies. DBA stained cells were sorted into five populations:
DBA+, DBA+; Pdx1:Egfp+, DBA-; Pdx1:Egfpmed, DBA-; Pdx1:Egfp high and DBA-; Pdx1:Egfp-.
The cells from each of these categories were cultured as described below.
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RNA was isolated from fixed cells using Magmax FFPE total nucleic acid isolation kit
(Ambion Life technologies) which involves reversing crosslinks, total nucleic acid isolation,
DNAse digestion, and purification of RNA. RNA was converted into cDNA using the Biorad
iScript cDNA synthesis kit. cDNA preamplified with Taqman probes (up to 7–10 probes were
combined in one reaction) diluted 100-fold. The preamplified cDNA was then subjected to
qPCR analysis against gene-specific Taqman probes. All qPCR values were normalized to
Gapdh.
Chromatin Immunoprecipitation (ChIP)-qPCR
FACS sorted cells were spun down and resuspended in 300 μl of freshly prepared cell lysis
buffer (3 mM MgCl2, 10 mM NaCl, 10 mM Tris pH 8.0, 0.1% Igepal, 1 tablet of Roche com-
plete mini protease inhibitors, EDTA free) for 30 min on ice. The cells were subsequently spun
down at 5000 rpm for 5 minutes at 4˚C. The fragmented cells were resuspended in 50–500 μl
nuclear lysis buffer depending on the number of cells obtained (50 mM Tris-Cl, pH 8.0, 10
mM EDTA, 1% SDS, 1 tablet of complete mini protease inhibitors, EDTA free). The suspen-
sion was incubated on ice for 15 min, flash frozen, and stored at -80˚C for future analysis. The
nuclear lysates containing chromatin were sonicated in a Diagenode bioruptor. Sonication
was carried out in 5 min pulses (2.5 min on, 2.5 min off) followed by 5 min rest on ice. This
procedure was carried out until chromatin was sonicated to 100–300 bp. Chromatin sonica-
tion was assessed by taking an aliquot of chromatin, reversing the crosslinks, and analyzing on
3% agarose gels. For chromatin immunoprecipitation (ChIP), approximately 20,000 cells were
diluted at least 5-fold in ChIP buffer (Active Motif High Sensitivity kit) and incubated with
4 μg of desired antibody or IgG on an end-to-end rotator at 4˚C overnight. Subsequently, Pro-
teinG conjugated agarose beads were added to all samples and incubated on an end-to-end
rotator for 3 hrs at 4˚C. The chromatin samples were then loaded on ChIP filtration columns
and washed 5 times with wash buffer AM1 (Active Motif High Sensitivity kit). One fifth to one
tenth of the chromatin samples were kept aside for input DNA preparation. Reverse crosslink-
ing of input and ChIP DNA was perfomed as described: samples were incubated with 1.25 M
NaCl and incubated overnight at 65˚C with moderate shaking. RNA was subsequently digested
with 0.15 μg/μl final concentration of RNaseA (Roche) for 1 hr at 37˚C. The samples were then
incubated with 0.4 μgm/μl of Proteinase K (Roche) for 2 hrs at 55˚C and then 2 hrs at 80˚C.
DNA was purified by two phenol-chloroform extractions and one aqueous phase isolation
from chloroform, followed by precipitation in 0.1 M NaCl, 0.037M glycogen and 2x volume of
100% ethanol, stored at -80˚C for 48 hrs, and then spun down at 13,000 rpm for 30 min. The
pellet was washed with 70% ethanol, dried, and resuspended in 40 μl of elution buffer. Follow-
ing antibodies were used for ChIP assays: H3S28ph (Ab5169, GR64943-1), H3K79me2 (Milli-
pore 04–835), H3K14acetyl (07–353), H4R3me2 (Ab5823), H3K9ac (Ab10812), H3K27ac
(Ab4279), H3K18ac (Ab1191-25), H3S10ph (Millipore 07–352, Ab5176), Msk1ph (Ab81294),
Msk2ph (PA5-39748). All the ChIP reactions were normalized to input and calculations were
done by 2 (Ct input-Ct antigen)/ (Ct input-Ct IgG) method. All the statistical analysis was performed by
paired Student’s t-test comparing the ratio of enrichment of antigen over IgG to 1. Any value
more than 1 indicates enrichment over IgG while a value equal to less than 1 is of no impor-
tance as it indicates negative enrichment over background (IgG). Therefore, one-tailed t test
was performed with the following thresholds:  0.05, 0.01, 0.001.
For qPCR, chromatin samples were diluted 5 times and the following recipe was used per
well: 2X Sybr green (10 μl), 0.2 μM forward+ reverse primer, 5 μl diluted ChIP DNA. The for-
ward and reverse primers used for qPCR analysis were as follows:
Insulin1(-400bp):forward5’ CATATCTTGGGTTGTTGGGTATTG 3’
reverse5’ CCTTCTCCATCTCTCCTTTCA C 3’
Msk Represses Pancreatic Beta Cell Fate
PLOS ONE | DOI:10.1371/journal.pone.0166703 December 14, 2016 22 / 31
Insulin1(+15bp):forward5’ CCATCAGCAAGCAGGTATGT 3’
reverse5’ CTGAAAGATAGGCAGGGTTGAG 3’
Insulin2(-200bp):forward5’ GCCCTTAATGGGTCAAACAG3’
reverse5’ GCTGGTGGTTACTGGGT3’
Onecut1(-220bp):forward5’ TGTACCGGGAACTAGCAACT 3’
reverse5’ CTTGCTACCTCCTGGTCTTC3’
Neurog3(-80bp):forward5’ CTGCCCTTTGTCCGGAATC3’
reverse5’ GCACCACGGGCCAATCAG3’
Gapdh:forward5’ CTACCTTAAATGAGAGCCGAGAG 3’
reverse5’ GCTCCTAGGGTTCGATTTCTT 3’
Amylase2a(-300bp):forward5’ TTGGAATGGTGCAATACAAAGA3’
reverse5’ CCAACCCGTACAAGGAGAATTA3’
Sox9 (-64bp):forward5’ AGCGACTTGCCAACACTGATGACT 3’
reverse5’ TGGTAAAGTTGTCGCTCCCACAGA 3’
Ptf1a(-350bp):forward5’ AGTCTGATGATGGCATGGGAAC 3’
reverse5’ TCAGAGACCGATTGGAGACATTT3’
Pdx1enh(area II enhancer):forward5’ GGAAATCCTTCCCTCAAGTTTT3’
reverse 5’ GTAAATTGGCTTCCATCTCGAC3’
Pdx1 (-340bp):forward5’ CTACAAAATTAGACCTCCACCC3’
reverse5’ AAAGTCTACATCTCCTCTTCCC3’
Culture of DBA; Pdx1:Egfp FACS sorted cells at E15.5
Two to three days prior to the experiment, OP9 feeder cells were plated to a sub-confluent den-
sity in 24-well tissue culture plate. On the day of the experiment, pancreata were dissected
from E15.5 embryos, treated with 0.25% trypsin followed by three washes with PBS + 10%
FBS. The pancreatic cell suspension was incubated with rhodamine conjugated to DBA (1:200)
at 4˚C for 40 min in PBS + 10% FBS, followed by three washes and FACS sorting. Approxi-
mately 2000–3000 cells from each fluorescence category were plated on OP9 feeder layers and
an aliquot of cells was kept for RNA analysis at t = 0. In addition, OP9 cells alone, with and
without inhibitors, were used to assess effects of inhibitors on feeder layers. cDNA was pre-
pared using Biorad iscript cDNA synthesis kit and qPCR analysis performed with Taqman
probes using the following recipe: 5 μl 2X Taqman master mix (Applied Biosystems), 0.5 μl
20X probe (Life technology) in 10 μl reaction. Identical amounts of RNA were used for cDNA
synthesis and all values were normalized to Gapdh.
Explant assays
After dissection of pancreata from E12.5 or E15.5 embryos, explants were cultured at the air-
liquid interface on 0.22 μm Nucleopore etched membranes. The media (1 g/L glucose DMEM,
10% FBS, 1X Pen-Strep) was changed on the second day and harvested on days 1, 4, and 8,
depending on the experiment. DMSO, at the same concentration as the inhibitor treated
explants, was used as controls for inhibitor treatments.
Immunofluorescence analysis of pancreatic explants
Pancreatic explants were fixed overnight at 4˚C in 4% formaldehyde. The explants were subse-
quently moved to 30% sucrose overnight. The tissue was then embedded in OCT freezing
medium and stored at -80˚C. The embryonic explants were cut in 6 μm sections, fixed, and
dried on Superfrost Plus slides (Thermo Scientific) at RT for at least 4 hours and stored at
-80˚C. For immunohistochemistry, slides were washed in PBS+0.1% Triton (PBT), boiled in
citrate buffer (10 mM Citric Acid, pH 6) (this treatment depends on the antibody), blocked for
non-specific epitopes using 10% FBS+ 1% BSA + 0.1% triton in PBS, incubated overnight in
primary antibody, followed by 4X, 15 min washes in PBT, incubated with secondary antibody
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(HRP conjugated or Alexa fluor conjugated), followed by 4X, 15 min washes in PBT. Signal
was developed either using Tyramide Signal Amplification kit (Invitrogen, 1:100 dilution of
substrate in TSA amplification buffer) or DAB (Vector Labs). For double staining, the sections
were citrate boiled again after first round of staining and the whole protocol was repeated. For
Insulin1-Glucagon (Gcg) double staining, no citrate buffer boiling was performed and the pro-
tocol was modified to avoid cross reaction in the following way: Sections were treated FIRST
with goat polyclonal anti-Gcg antibody (primary), donkey anti-goat HRP (secondary) and
developed using TSA reagents as mentioned above. This was followed by incubation with
guinea pig anti-Insulin1 antibody at 4˚C, followed by treatment with goat biotinlyated anti-
guinea pig IgG overnight at 4˚C and streptavidin-HRP for 2 hrs at RT, and developed by TSA
reagents using a different fluorophore. The Insulin1 positive area and total area were calculated
at two different thresholds using ImageJ software. Beta cell mass was calculated by dividing
insulin positive area by total pancreatic area. The pictures were acquired on NIS elements soft-
ware. The following antibodies were used: Msk1ph (1:200, Ab81294), Msk2ph (1:100, PA5-
39748, Thermo Scientific), Insulin (1:100, Ab7842), Amylase (1:200, A8273, Sigma), Glucagon
(1:1000, SC-7779 and Ab10988), Onecut1 (1:300, H-100, SC-13050), Pdx1 (1:500, Ab2031,
Beta cell body consortium), Egfp (1:1000, Ab290), Neurog3 (1:100, F25A1B3-b), Cleaved Cas-
pase3 (1:200, Cell signaling, 9661S) and anti BrDU (1:10, Roche, 11299964001), MafA (1:100,
Bethyl Labs, 00352).
Western Blotting
E15.5 explants cultured in either SB747541A or DMSO for 1 day were homogenized in hypo-
tonic buffer (10 mM Tris, 10 mM NaCl, 3 mM MgCl2, 0.5% NP-40, 5 mM EDTA, 2.5 mM Na-
fluoride, 2 mM sodium orthovanadate, fresh protease inhibitors from Roche) and incubated
on ice for 30 min. Cell lysates were spun down at 4˚C and the nuclear pellets were resuspended
in RIPA buffer (0.05 M Tris, 0.15 M NaCl, 1% NP-40, 0.5% deoxycholate, 1% SDS). The nuclei
were sonicated for 1 min with a Diagenode bioruptor (30 sec on, 30 sec off) and protein con-
centration measured by Bicinchoninic Acid assay (Pierce Biotechnology). Samples were sepa-
rated on 4–12% Bis Tris polyacrylamide gels and transferred to activated PVDF membranes.
The membranes were blocked with 10% dry milk in TBST (0.1% Triton) overnight, followed
by primary antibody for 2 hrs or overnight, 3X 5’ washes in TBST, HRP-conjugated secondary
(1:4000), 3X 5’ washes in TBST (0.1% Triton) washes and developed by Super Signal West-
pico or West-femto chemiluminescent reagent, depending on the sensitivity of antibody and
abundance of antigen. For reprobing the blot, membranes were treated with stripping buffer
(Thermo Scientific) for 2–3 hrs, followed by 10% dry milk in TBST and proceeded with stain-
ing as mentioned above.
Islet isolation from pancreas
Islets were isolated from pancreata from 2–3 month old wild type mice using the method of
Szot et al. J. Vis. Exp. 2007 [72] with minor modifications. In brief, pancreata were perfused
through common bile duct with freshly prepared Collagenase P (0.09 gm/100 ml HBSS,
Roche). Inflated pancreas were subsequently removed and digested with Collagenase P at
37˚C. Collagenase was removed by two washes in HBSS + 0.02% BSA. Subsequently, digested
pancreata were subjected to Ficoll density gradient centrifugation (5 ml of 27%, 2.5 ml of 23%,
2.5 ml of 10.5%, 2.5 ml of 11%). Islets were hand-picked from top three layers of the gradient.
ELISA
The ELISA assay was performed on pancreatic lysates using EZRMI-13K kit.
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Statistical Methods
All P-values were calculated by Student’s t test, comparing DMSO and SB-747651A treated
samples in independent experiments, 0.05, 0.01, 0.001 (Figs 3, 4, 5 and 6). For
ChIP, all P-values were calculated by paired Student’s t test, comparing enrichment over IgG
in independent experiments,  0.05,  0.01, 0.001, one-tailed (Figs 1, 2 and 8).
Supporting Information
S1 Fig. Onecut1 staining in E15.5 pancreata, sorting and expression analysis of E12.5
Pdx1:Egfppancreatic cells using FACS and RT-qPCR respectively. (A-C) Epifluorescence
imaging of Oc1 (red) and Insulin1/2 in pancreatic sections from E15.5 stage. (D) FACS Sort of
EGFP cells from Pdx1: Egfp at E12.5 (n15 biological replicates). (E) RT-qPCR analysis of
select genes in E12.5 Pdx1:Egfppositive cells relative to Pdx1:Egfpnegative cells
(TIF)
S2 Fig. Epifluorescent images from select experiments. (A-D) Epifluorescence images show-
ing nuclear expression of Msk1S360ph and Msk2T586ph at low and high magnifications in
pancreatic sections from E15.5 stage. (E-F) Pdx1 immunostaining on sections from pancreatic
explants treated with DMSO and SB747541A from E12.5 stage for 4 days. (G-H) Pdx1 and
Insulin1/2 coimmunostaining on sections from pancreatic explants from E15.5 stage treated
with DMSO and SB747541A for 4 days. (I-L) Images showing low cell density cultures of live
Pdx1:Egfpmedium and Pdx1:Egfphigh cells treated with SB747541A after one day of culture.
Arrows show that the sorted Pdx1:Egfp+pancreatic cells are in minimal contact with each
other. (M-T) Insulin1/2 immunostaining on sections from pancreatic explants treated with
DMSO and SB747541A from E15.5 stage, for 4 days and the corresponding brightfield images
(Q-T).
(TIF)
S3 Fig. Western blot and quantification of H3S28ph and H3S10ph levels in pancreas from
the indicated genotype (A-D).
(TIF)
S4 Fig. Expression analysis of the indicated genes in the dmso and SB747541A treated pan-
creatic explants at different developmental stages. (A, B) Expression of indicated genes in
dmso treated controls at day1 (grey) and day4 (blue) of culture, by RT-qPCR. (C, D) Immuno-
histochemistry for Insulin1/2 on pancreatic sections from E12.5 explants cultured for 1 (C) or
4 days (D). (E-J) RT-qPCR analysis of indicated genes in pancreatic explants from E12.5 or
E15.5 stage treated with SB747541A for 4 days. This is a composite data from Figs 3B, 4B and
5A–5D. Values are a ratio of normalized expression in SB747541A and normalized expression
in DMSO, two independent experiments ± standard error.
(TIF)
S5 Fig. Neurog3 and Amylase co-staining on day1 of SB747541A treatment in E15.5
explants. (A-F) Immunohischemical staining, showing co-expression of Neurog3 and Amy-
lase, on pancreatic sections from E15.5 explants cultured in DMSO or SB747541A, cultured
for one day. Panels A, B, D, E show single color images of the Neurog3 (A, D) or Amylase (B,
E).
(TIF)
S6 Fig. Analysis of cell division and apoptosis upon SB747541A treatment at the indicated
days after inhibitor treatment. (A-C) anti-BrdU staining on Day4 on explants treated with a
pulse of BrdU for 8hours on day 1. Total number of BrdU positive cells normalized to total
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area was not significantly different between DMSO and SB747541A. (D-I) Staining and quan-
tification of Cleaved Caspase3 (D-F) and TUNEL staining (G-I) on day 1 of Msk1/2 inhibition
upon harvesting pancreas form E15.5. (J-O) Staining and quantification of Cleaved Caspase3
(J-L) and TUNEL staining (M-O) on day 4 of Msk1/2 inhibition, upon harvesting pancreas
from E15.5. Areas were calculated using either the Histogram function of Adobe Photoshop
program or by ImageJ.
(TIF)
S7 Fig. RT-qPCR analysis of different sorted populations, from DBA; Pdx1:Egfp double
facs sort, at the time of isolation and 3 days into the culture. (A) FACS scatter plots of single
cell suspension from E15.5 Pdx1:Egfppancreata treated without DBA or with DBA, as indi-
cated. (B, C) Expression analysis by RT-qPCR of indicated genes in different populations
obtained from FACS sorting at the time of isolation (B) and 3 days of culture (C). The y-axis
shows relative enrichment.
(TIF)
S8 Fig. Expression analysis of Gcg, Ins1/2 and Amylase in Msk1 and Msk2 mutants. (A-T)
Representative images showing expression of Glucagon (A-E, scale bar = 50μm), Insulin (F-J,
scale bar = 50μm) and Amylase (K-O, scale bar = 100μm,) and corresponding brightfield
images (P-T) of Amylase positive domains in the indicated genotypes at E15.5. (U-W) Gluca-
gon, Insulin, and Amylase positive areas normalized to total area in the indicated genotypes at
E15.5. For Gcg, P-values are 0.01 for Msk1+/-, 3.3x10-7 for Msk1-/-, 2.2x10-4 for Msk2+/-, 0.02
for Msk2-/-, 2.2x10-6 for Msk1+/-; Msk2+/- and 3.1x10-5 for Msk1-/-;Msk2-/-. For Ins1, P-
value = 1.5x10-5 for Msk1+/-. For Amyl, P-values are 3.3x10-13 for Msk2+/-, 0.004 for Msk1+/-;
Msk2+/-, 1.7 x10-6 for Msk1-/-;Msk2-/-. Average number of sections/pancreas for Ins1 and Gcg
respectively were 17, 9.8 (wild type), 17.83, 5.6 (Msk1+/-), 15.6, 5 (Msk1-/-), 16.3, 5 (Msk2-/-),
14.75, 6.375 (Msk2+/-), 13, 13.5 (Msk1+/-; Msk2+/-), 15.12, 6.75 (Msk1-/-; Msk2-/-). All
P-values were calculated by Student’s t test, relative to wild type controls,  0.05,  0.01,
0.001, unequal variance, two-tailed. Values are averages of independent
experiments ± standard error unless otherwise stated
(TIF)
S9 Fig. Representative example illustrating the calculation of area using ImageJ and
images of Gcg, Ins1/2 and Amylase from Msk2-/- and Msk1+/-;Msk2+/- pancreata. (A-C)
Representative pictures demonstrating the calculation of Insulin positive area by ImageJ. The
original fluorescent images for calculating Insulin positive area is shown in panel A. Represen-
tative binary pictures, thresholded by ImageJ, demonstrating Insulin positive domain (B) and
total pancreatic area of the same specimen by ImageJ (C) The image was first rendered to
binary and then the numbers of particles were calculated at two different thresholds for Insulin
positive area (B) and total area (C) respectively by ImageJ software. (D-F) Immunohistochemi-
cal staining of Gcg, Ins1, and Amylase2a in the pancreatic sections at E15.5 stage from the
indicated genotypes.
(TIF)
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